Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 230 of the 238 references it cites were found in a registry or an index; 51 of the 243 sources its claims cite were checked for support.

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

Open access

Abstract

Recombinant adeno-associated viruses (AAVs) have emerged as promising gene delivery vehicles resulting in three US Food and Drug Administration (FDA) and one European Medicines Agency (EMA)-approved AAV-based gene therapies. Despite being a leading platform for therapeutic gene transfer in several clinical trials, host immune responses against the AAV vector and transgene have hampered their widespread application. Multiple factors, including vector design, dose, and route of administration, contribute to the overall immunogenicity of AAVs. The immune responses against the AAV capsid and transgene involve an initial innate sensing. The innate immune response subsequently triggers an adaptive immune response to elicit a robust and specific response against the AAV vector. AAV gene therapy clinical trials and preclinical studies provide important information about the immune-mediated toxicities associated with AAV, yet studies suggest preclinical models fail to precisely predict the outcome of gene delivery in humans. This review discusses the contribution of the innate and adaptive immune response against AAVs, highlighting the challenges and potential strategies to mitigate these responses, thereby enhancing the therapeutic potential of AAV gene therapy.

Overview

CoChat Summary

TL;DR

Recombinant AAV vectors are a leading gene-transfer platform, but innate and adaptive immune responses against the capsid, vector DNA, and transgene limit efficacy and safety. This review summarizes those immune mechanisms and the preclinical/clinical strategies being developed to mitigate them.

Key findings

  • AAV-based therapies have reached the clinic: three FDA-approved products (Luxturna, Zolgensma, HEMGENIX) and one EMA-approved AAV5-Factor 8 vector (Roctavian).
  • Pre-existing anti-AAV neutralizing antibodies are common, with 2–60% of human sera containing antibodies that limit AAV gene therapy depending on capsid variant; anti-AAV2 and AAV1 NAbs are most prevalent, and 10–100% of healthy human subjects have functional circulating capsid-specific T cells against multiple AAV serotypes.
  • High-dose intravenous AAV can trigger complement activation and thrombotic microangiopathy (TMA): in DMD and SMA1 trials, patients receiving >1×10^14 vg/kg presented with complement activation/TMA, and TMA was reported in two MMA patients who received 5×10^13 vg/kg AAV-LK03.
  • Zolgensma is administered at 1.1×10^14 vg/kg; among >1400 treated patients, the FDA reported nine TMA cases, and the EMA reported five TMA cases among 800 patients.
  • Mitigation strategies under study include CpG depletion, TLR9 inhibition, complement inhibitors (APL-9, eculizumab), immunosuppression, capsid engineering, plasmapheresis, ImmTOR, and Treg-based approaches.

Methods

  • Narrative review of published preclinical and clinical literature on AAV immunogenicity, including innate sensing, complement activation, humoral and T-cell responses, transgene immunity, and post-approval safety data.
  • No primary experimental data, systematic search strategy, or meta-analysis is reported; the paper synthesizes findings from AAV gene therapy trials, animal studies, and post-licensure surveillance.
  • Main analysis is descriptive, organized around immune mechanisms and candidate mitigation strategies, with a summary table of strategies and their clinical status.

Limitations

  • The paper states that much remains unknown about immune responses to AAV gene therapy in patients, that lack of standard immune-assay protocols and inability to collect relevant samples cause variability across studies, and that appropriate animal models are not readily available.
  • The paper states that preclinical models fail to precisely predict gene-delivery outcomes in humans, and that variability in dose, route, and capsid serotypes complicates comparison and interpretation.
  • Evident from the text: as a narrative review, it does not provide a systematic search, quantitative synthesis, or primary data to resolve the variability it describes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40259-023-00585-7

Cites

230 of 230 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Immune responses in AAV gene therapy. AAV capsid or introduced transgene can be recognized by innate immunity which results in cytokine production, activation of innate immune cells, complement activation, and priming of adaptive immunity. Presentation of capsid peptides or delivered transgene on MHC I molecules results in activation of CD8+ T cells and clearance of transgene expression. Antigen presentation on MHC II activates CD4+ T cells, which leads to production of cytokines and further induces humoral or cell-mediated immune responses and creates immunological memory. Activation of Tregs results in suppression of cellular and humoral immune responses and long-term transgene expression. AAV adeno-associated virus, APCs antigen-presenting cells, FoxP3 forkhead box protein 3, GzmB granzyme B, IFNγ interferon gamma, MHC major histocompatibility complex, NAbs neutralizing antibodies, PFN perforin, rAAV recombinant adeno-associated virus, TCR T-cell receptor, TLR9 toll-like receptor, TNFα tumor necrosis factor alpha, Tregs regulatory T cells
Fig. 1 Immune responses in AAV gene therapy. AAV capsid or introduced transgene can be recognized by innate immunity which results in cytokine production, activation of innate immune cells, complement activation, and priming of adaptive immunity. Presentation of capsid peptides or delivered transgene on MHC I molecules results in activation of CD8+ T cells and clearance of transgene expression. Antigen presentation on MHC II activates CD4+ T cells, which leads to production of cytokines and further induces humoral or cell-mediated immune responses and creates immunological memory. Activation of Tregs results in suppression of cellular and humoral immune responses and long-term transgene expression. AAV adeno-associated virus, APCs antigen-presenting cells, FoxP3 forkhead box protein 3, GzmB granzyme B, IFNγ interferon gamma, MHC major histocompatibility complex, NAbs neutralizing antibodies, PFN perforin, rAAV recombinant adeno-associated virus, TCR T-cell receptor, TLR9 toll-like receptor, TNFα tumor necrosis factor alpha, Tregs regulatory T cellsCC BY-NC · PubMed Central

Verification

Claims the paper makes

37 Valid · 7 Not valid · 118 Not checked · 36 Own results and interpretations

117 more claims · 19 with their cited sources checked

Create a free account to see all 198 claims and to verify the 192 references still open.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 66

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 238 references

Research works printed but not linked: 8

  1. LogicBio. LogicBio therapeutics reports second quarter 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. LogicBio; 2022.
  2. Shirley JL, et al. Type I IFN sensing by cDCs and CD4+ T cell help are both requisite for cross-priming of AAV capsid-specific CD8+ T cells. Mol Ther. 2020;28(3):758–70. · DOI · Paper page
  3. Rogers GL, et al. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8+ T cells. Blood. 2017;129(24):3184–95. · DOI · Paper page
  4. Sullivan L. Apellis pharmaceuticals will commence APL-9 program to control the complement system in host responses to AAV vector administration for gene Therapies. Appellis Pharmaceuticals; 2019.
  5. Schroeder, H., et al. Functional assessment of T cell responses to AAV8 empty capsids in healthy volunteers. Molecular Therapy. 2022;30(4):19-20.
  6. Calcedo R, et al. Immune responses in 101HEMB01, a Phase 1/2 open-Label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with severe hemophilia B. Blood. 2017;130:3333.
  7. Samelson-Jones BJ, et al. Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates. Mol Ther-Methods Clin Dev. 2020;17:1129–38. · DOI · Paper page
  8. Li C, et al. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Investig. 2013;123(3):1390–401. · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M.
Affiliations
University of Massachusetts Chan Medical School (US)
Corresponding author
Keeler, Allison M.
Venue
BioDrugs
Published
2023-03-02
Volume
37
Issue
3
Pages
311-329
ISSN
  • 1172-7039 (ISSN-L)
  • 1173-8804
  • 1179-190X
OpenAlex
W4322758747
Cited by
159
References
238
Citations by year
2026: 45 · 2025: 52 · 2024: 49 · 2023: 13
FWCI
6.14
Type
journal article
Language
en
Open access
Licence
Locations
  • BioDrugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
NHLBI Division of Intramural Research (P01 HL158506)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
recombinant adeno-associated virus vectors, gene therapy, innate immune response, adaptive immune response, AAV capsid, immune-mediated toxicity, preclinical models, vector design, route of administration
MeSH terms
Dependovirus, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. https://app.cochat.ai/papers/10.1007/s40259-023-00585-7
The paper
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023). Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer. BioDrugs. https://doi.org/10.1007/s40259-023-00585-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.